WO2005120565A8 - Sars vaccines and methods to produce highly potent antibodies - Google Patents

Sars vaccines and methods to produce highly potent antibodies

Info

Publication number
WO2005120565A8
WO2005120565A8 PCT/US2005/019266 US2005019266W WO2005120565A8 WO 2005120565 A8 WO2005120565 A8 WO 2005120565A8 US 2005019266 W US2005019266 W US 2005019266W WO 2005120565 A8 WO2005120565 A8 WO 2005120565A8
Authority
WO
WIPO (PCT)
Prior art keywords
functional fragment
igg
antigen
sequence
methods
Prior art date
Application number
PCT/US2005/019266
Other languages
French (fr)
Other versions
WO2005120565A3 (en
WO2005120565A2 (en
Inventor
Shibo Jiang
Yuxian He
Shuwen Liu
Original Assignee
New York Blood Ct Inc
Shibo Jiang
Yuxian He
Shuwen Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc, Shibo Jiang, Yuxian He, Shuwen Liu filed Critical New York Blood Ct Inc
Priority to EP05786720A priority Critical patent/EP1773388A4/en
Priority to AU2005251738A priority patent/AU2005251738A1/en
Priority to CA002569142A priority patent/CA2569142A1/en
Publication of WO2005120565A2 publication Critical patent/WO2005120565A2/en
Publication of WO2005120565A8 publication Critical patent/WO2005120565A8/en
Publication of WO2005120565A3 publication Critical patent/WO2005120565A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention provides a vaccine comprising an effective amount of an isolated polypeptide or recombinant protein containing the sequence of the receptor-binding domain in the SARS associated coronavirus spike protein or a functional fragment thereof, or a nucleic acid molecule comprising the sequence of a fragment which encodes the sequence of the receptor-binding domain in the Severe Acute Respiratory Syndrome associated coronavirus spike protein or a functional fragment thereof. This invention provides a composition for increasing the immunogenicity of an antigen comprising an effective amount of an antigen and an IgG Fc domain, its functional fragment, or a substance containing an IgG Fc domain or its functional fragment. The antigen and the IgG Fc may be linked or unlinked. Finally, this invention also provides method for using any of the above compositions for immunization.
PCT/US2005/019266 2004-06-02 2005-06-01 Sars vaccines and methods to produce highly potent antibodies WO2005120565A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05786720A EP1773388A4 (en) 2004-06-02 2005-06-01 Sars vaccines and methods to produce highly potent antibodies
AU2005251738A AU2005251738A1 (en) 2004-06-02 2005-06-01 SARS vaccines and methods to produce highly potent antibodies
CA002569142A CA2569142A1 (en) 2004-06-02 2005-06-01 Sars vaccines and methods to produce highly potent antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57611804P 2004-06-02 2004-06-02
US60/576,118 2004-06-02
US14192505A 2005-05-31 2005-05-31
US11/141,925 2005-05-31

Publications (3)

Publication Number Publication Date
WO2005120565A2 WO2005120565A2 (en) 2005-12-22
WO2005120565A8 true WO2005120565A8 (en) 2006-02-09
WO2005120565A3 WO2005120565A3 (en) 2007-05-18

Family

ID=35503665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019266 WO2005120565A2 (en) 2004-06-02 2005-06-01 Sars vaccines and methods to produce highly potent antibodies

Country Status (4)

Country Link
EP (1) EP1773388A4 (en)
AU (1) AU2005251738A1 (en)
CA (1) CA2569142A1 (en)
WO (1) WO2005120565A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021160036A1 (en) * 2020-02-10 2021-08-19 Versitech Limited Compositions immunogenic against sars coronavirus 2, methods of making, and using thereof
JP2023515800A (en) * 2020-02-19 2023-04-14 ユナイテッド・バイオメディカル・インコーポレーテッド Designer Peptides and Proteins for Detection, Prevention and Treatment of Coronavirus Disease 2019 (COVID-19)
CN113321715B (en) * 2020-02-28 2023-02-17 北京万泰生物药业股份有限公司 Novel coronavirus antigen and detection use thereof
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
WO2021195089A1 (en) * 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
CN111983226A (en) 2020-03-25 2020-11-24 新加坡国立大学 Detection of SARSr-CoV antibodies
CN113461828B (en) * 2020-03-30 2023-10-27 北京科兴中维生物技术有限公司 Recombinant protein vaccine for 2019-nCoV and preparation method thereof
CN111574622A (en) * 2020-04-07 2020-08-25 刘会芳 Antibody for resisting novel human coronavirus pneumonia and preparation method thereof
CN113527444B (en) * 2020-04-13 2022-12-27 中国科学院微生物研究所 Epitopes effective binding to antibodies of novel coronaviruses
EP4150071A1 (en) * 2020-05-11 2023-03-22 Lysando AG Virus neutralization by soluble receptor fragments of the ace-2 receptor
CN111574623A (en) * 2020-05-25 2020-08-25 西安咸辅生物科技有限责任公司 Preparation method of novel coronavirus S1+ S2 anti-idiotype yolk antibody vaccine
WO2021237516A1 (en) * 2020-05-27 2021-12-02 上海济煜医药科技有限公司 Sars-cov-2 antibody and application thereof
CN113230395B (en) * 2020-05-29 2022-07-19 中国科学院微生物研究所 Beta coronavirus antigen, beta coronavirus bivalent vaccine, preparation methods and applications thereof
EP3925971A1 (en) * 2020-06-16 2021-12-22 Viravaxx AG Method for identifying compounds influencing virus receptor binding
CN113797326B (en) * 2020-06-17 2024-01-19 上海君实生物医药科技股份有限公司 Vaccine for preventing diseases caused by coronaviruses
EP4182699A1 (en) * 2020-07-19 2023-05-24 Nantcell, Inc. Covid-19 mucosal antibody assay
CN111808199A (en) * 2020-07-27 2020-10-23 西安咸辅生物科技有限责任公司 Preparation method of ACE2 anti-idiotype yolk antibody vaccine
CN114057845A (en) * 2020-08-07 2022-02-18 清华大学 Polypeptide for preventing novel coronavirus pneumonia COVID-19, immunogenic conjugate and application thereof
CN112225814A (en) * 2020-09-29 2021-01-15 东莞博盛生物科技有限公司 Novel coronavirus RBD fusion protein subunit vaccine and preparation method and application thereof
CN112480268B (en) * 2020-12-10 2021-08-03 北京康乐卫士生物技术股份有限公司 Novel recombinant subunit vaccine of coronavirus and application thereof
CN116143938B (en) * 2021-02-04 2023-11-10 广东克冠达医药科技有限公司 COVID-19 subunit vaccine and preparation method and application thereof
GB2606693A (en) * 2021-04-08 2022-11-23 Exosis Inc Fusion protein
CN113583137B (en) * 2021-06-15 2022-08-05 北京康乐卫士生物技术股份有限公司 Novel recombinant subunit vaccine of coronavirus south Africa mutant strain and application thereof
CN116375881A (en) * 2021-12-31 2023-07-04 广州国家实验室 Fusion protein vaccine

Also Published As

Publication number Publication date
AU2005251738A1 (en) 2005-12-22
EP1773388A4 (en) 2008-08-20
EP1773388A2 (en) 2007-04-18
CA2569142A1 (en) 2005-12-22
WO2005120565A3 (en) 2007-05-18
WO2005120565A2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
WO2005120565A8 (en) Sars vaccines and methods to produce highly potent antibodies
WO2007084583A3 (en) Soluble fragments of the sars-cov spike glycoprotein
WO2007011904A3 (en) Recombinant flu vaccines
WO2007098201A3 (en) Shiga toxoid chimeric proteins
WO2006036550A3 (en) Listeria-based and llo-based vaccines
IN2009CN03372A (en)
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
WO2002080851A3 (en) Chimeric vaccines
WO2006083301A3 (en) Immunogenic compositions comprising hmgb1 polypeptides
WO2006032472A3 (en) Immunogenic composition for use in vaccination against staphylococcei
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
ATE461295T1 (en) METHOD AND COMPOSITIONS FOR VACCINATION OF ANIMALS WITH PRRSV ANTIGENS WITH IMPROVED IMMUNOGENICITY
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
WO2008009652A3 (en) Vaccines for malaria
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
WO2007050095A3 (en) Improved vaccines and methods for using the same
TW200510450A (en) Soluble fragments of the SARS-CoV spike glycoprotein
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2006091824A3 (en) Peptides for detection of antibody to porcine reproductive respiratory syndrome virus
MX2024004293A (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus.
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
WO2005007673A3 (en) Immunogenic peptides
WO2008118487A3 (en) Compositions and methods for incresing immunogenicity of glycoprotein vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 51/2005 ADD "DECLARATION UNDER RULE 4.17: - AS TO THE APPLICANT S ENTITLEMENT TO CLAIM THE PRIORITY OF THE EARLIER APPLICATION (RULE 4.17(III)) FOR ALL DESIGNATIONS."

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2569142

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005786720

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005251738

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005251738

Country of ref document: AU

Date of ref document: 20050601

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005251738

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580026179.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005786720

Country of ref document: EP